Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
22.42%
Operating Margin
1.99%
Net Margin
-19.73%
Efficiency Metrics
Revenue per Expense Ratio
1.02
R&D as % of Revenue
0.84%
Earnings Quality
EBITDA Margin
-0.03%
Income Tax Rate
848,100,000.0%
EPS
-2.3800000000
Balance Sheet Analysis
Current Ratio
1.42
Cash Ratio
0.20
Working Capital
$147.40M
Debt to Equity
436,340,000.0
Debt to Assets
56.25%
Equity Ratio
-25.91%
Cash Flow Analysis
Operating Cash Flow Ratio
-4.23%
Free Cash Flow Ratio
-5.21%
CapEx to Revenue
0.98%
Dividends Paid
$11.14M
Stock Buybacks
$1.41M
Total Shareholder Returns
$12.56M
Cash Position Change
-22.42%
Key Takeaways (2023 FY)
Increased R&D investment by 122.21%
Detailed Growth Metrics
Core Performance
Revenue
12.31%
Net Income
-641.38%
EPS
-693.33%
Operating Income
-31.62%
Operational Efficiency
R&D Expenses
122.21%
SG&A Expenses
2.39%
Operating Cash Flow
-38.14%
Free Cash Flow
-18.88%
Balance Sheet Health
Assets
-17.72%
Debt
5.93%
Book Value per Share
-9,359.55%
Inventory
11.00%
Shareholder Returns
Dividends per Share
-25.64%
Shares Outstanding
0.86%
Long Term Trends
3Y Revenue/Share
-3.43%
5Y Revenue/Share
-85.39%
3Y Dividend/Share
0.00%
5Y Dividend/Share
0.00%